---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-126223"
form_type: "8-K"
ticker: "LBRX"
cik: "0001691082"
company_name: "LB PHARMACEUTICALS INC"
filed_at: "2026-03-26T23:59:59+00:00"
generated_at: "2026-05-15T08:51:10.049127+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# LB Pharmaceuticals reports Q4 net loss $11.5M; cash $295.2M; advances LB-102 into Phase 3

## Summary
- Positive Phase 2 (NOVA-1) results for LB-102 in acute schizophrenia met primary endpoint; Phase 3 NOVA-2 initiated March 2026 with data expected H2 2027.
- Phase 2 ILLUMINATE-1 trial in bipolar depression started Jan 2026; Phase 2 for adjunctive MDD planned early 2027.
- September 2025 IPO raised $327.8M (21.85M shares at $15); February 2026 private placement added $100M.
- Cash and investments $295.2M at Dec 31, 2025; with private placement, runway into Q2 2029.
- Q4 2025 net loss $11.5M ($5.1M Q4 2024); full-year net loss $25.2M ($63.1M 2024); R&D expenses declined YoY.

## SEC filing metadata
- accession: 0001193125-26-126223
- form_type: 8-K
- ticker: LBRX
- cik: 0001691082
- company_name: LB PHARMACEUTICALS INC
- filed_at: 2026-03-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1691082/000119312526126223/0001193125-26-126223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1691082/000119312526126223/d129775d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-126223
- JSON: https://secwatch.observer/filing/0001193125-26-126223.json
- Plain text: https://secwatch.observer/filing/0001193125-26-126223.txt

## Key facts
- Earnings Releases
  LB PHARMACEUTICALS INC reported financial results for fourth quarter and full year ended December 31, 2025.
  - Period: fourth quarter and full year ended December 31, 2025
  - Result: reported results
  source text: On March 26, 2026, LB Pharmaceuticals Inc (the “Company”) issued a press release announcing its financial results for the three months and full year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1691082/000119312526126223/0001193125-26-126223-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.